Sign In
Buy OMER
$10.16
-0.1000 (-0.97%)
At Close: Jun 03, 2026
Recap: Omeros Q4 Earnings
04:18pm, Monday, 01'st Mar 2021
Shares of Omeros (NASDAQ:OMER) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 3.45% over the past year to ($0.60), which beat the es
Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results
04:02pm, Monday, 01'st Mar 2021
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeuti
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on March 1, 2021
09:37am, Thursday, 25'th Feb 2021
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2020, on Mo
Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for
01:39pm, Monday, 22'nd Feb 2021
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omeros: Multibagger On The Horizon
12:04pm, Wednesday, 10'th Feb 2021
Omeros' Biologics License Application (BLA) for orphan drug narsoplimab was accepted by FDA and was given priority review with FDA action date of July 17, 2021. This BLA is for the treatment of hemato
Omeros: On A Tear, More To Come
06:13am, Wednesday, 10'th Feb 2021
Omeros has doubled since my last (10/20) bullish article. The company is still vastly undervalued with its current market cap of ~$1.3 billion.
Omeros Hires Nadia Dac as Chief Commercial Officer
08:45am, Tuesday, 26'th Jan 2021
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commerci
Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA
08:30am, Tuesday, 19'th Jan 2021
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associa
Omeros to Present at the 39th Annual J.P. Morgan Healthcare Conference
04:30pm, Monday, 11'th Jan 2021
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 39th Annual J.P. Morgan Healthcar
Omeros: A Ripening Fruit Ready To Pick
04:02am, Wednesday, 09'th Dec 2020
Omeros: A Ripening Fruit Ready To Pick
CMS Confirms Continued Separate Payment for Omeros' FDA-Approved OMIDRIA® in Ambulatory Surgery Centers
07:30am, Thursday, 03'rd Dec 2020
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for
Omeros Corp (OMER) CEO Greg Demopulos on Q3 2020 Results - Earnings Call Transcript
09:58pm, Monday, 09'th Nov 2020
Omeros Corp (OMER) CEO Greg Demopulos on Q3 2020 Results - Earnings Call Transcript
The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat
12:00am, Thursday, 22'nd Oct 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 21)
Amicus Therapeutics, Inc. (...
The Week Ahead In Biotech: Spectrum Pharma FDA Decision, Biogen And Abbott Earnings, Cancer Conference
12:00am, Sunday, 18'th Oct 2020
Biopharma stocks, which started the week on a firm footing, lost momentum mid-way through amid market-wide sell-off triggered by waning stimulus hopes.
The week was a quiet...
Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit
12:00am, Friday, 16'th Oct 2020
Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit. OMS906 is the
